Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.37
-0.09 (-1.27%)
Oct 6, 2026, 2:38 PM EDT - Market open
Arvinas Revenue
Arvinas had revenue of $249.70M in the quarter ending June 30, 2026, with 1,014.73% growth. This brings the company's revenue in the last twelve months to $316.70M, down -15.05% year-over-year. In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%.
Revenue (ttm)
$316.70M
Revenue Growth
-15.05%
P/S Ratio
1.54
Revenue / Employee
$1,287,398
Employees
246
Market Cap
481.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Autolus Therapeutics | 117.39M |
| Assembly Biosciences | 74.85M |
| Capricor Therapeutics | 11.13M |
| Allogene Therapeutics | 4.64M |
| ProKidney | 818.00K |
| Entera Bio | 42.00K |
ARVN News
- 4 days ago - Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 6 days ago - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723 - TheFly
- 8 days ago - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate - GlobeNewsWire
- 20 days ago - Arvinas Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 26 days ago - Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Arvinas Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire